RCTs Supporting Bismuth-Containing Quadruple Therapy for H. pylori Eradication
The provided evidence does not contain specific names of individual randomized controlled trials that originally established bismuth quadruple therapy—rather, it references consensus guidelines that synthesized multiple RCTs 1. The major guidelines (Toronto Consensus, Maastricht V/Florence, and American College of Gastroenterology) all recommend bismuth quadruple therapy as first-line treatment based on accumulated evidence showing acceptable success even with metronidazole-resistant strains 1.
Recent RCTs Validating Bismuth Quadruple Therapy
While the guidelines don't name the foundational trials, several recent high-quality RCTs have directly tested bismuth quadruple therapy:
First-Line Treatment Studies:
"10-Day versus 14-day bismuth quadruple therapy for first-line eradication" (2024, EClinicalMedicine) 2
- Multicenter RCT (n=313) comparing 10-day vs 14-day bismuth quadruple therapy
- ITT eradication: 92.4% (10-day) vs 92.9% (14-day)
- Demonstrated non-inferiority of shorter duration
"Bismuth-Containing Quadruple Therapy for Helicobacter pylori Eradication: A Randomized Clinical Trial of 10 and 14 Days" (2024, Digestive Diseases and Sciences) 3
- Large multicenter Chinese RCT (n=1300)
- ITT eradication: 88.62% (10-day) vs 89.38% (14-day)
- Confirmed non-inferior efficacy with shorter duration
"Comparison between optimized bismuth quadruple therapy and standard clarithromycin-based triple therapy" (2026, Lancet Regional Health Americas) 4
- Chilean double-blind RCT (n=127)
- ITT eradication: 95% for optimized bismuth quadruple vs 81% for standard triple therapy (p=0.033)
- Demonstrated superiority in areas with high clarithromycin resistance
Rescue Treatment Studies:
- "Optimization of Minocycline-Containing Bismuth Quadruple Therapy" (2026, Journal of Gastroenterology and Hepatology) 5
- RCT (n=480) in refractory patients
- PP eradication: 98.2% for classical bismuth quadruple therapy
- Validated bismuth quadruple as effective rescue therapy
Important Context
The guidelines themselves represent the synthesis of numerous RCTs rather than citing individual trial names 1. The 2019 Gastroenterology reconciliation article specifically states that all three major consensus groups (Toronto, Maastricht V/Florence, ACG) recommend bismuth quadruple therapy based on accumulated evidence showing:
- Efficacy in areas of high dual resistance to clarithromycin and metronidazole
- Acceptable success even with metronidazole-resistant strains
- Avoidance of antibiotic overuse concerns
The foundational RCTs that established bismuth quadruple therapy are not individually named in the provided evidence, but the recent trials listed above (2024-2026) provide contemporary validation of this approach with eradication rates consistently exceeding 85-90% in both first-line and rescue settings.